LongBio Pharma FY26 H1 net loss widens 43.1% to RMB 134.81 million

• LongBio Pharma posted a net loss of RMB 134.81 million, widening 43.1% from a year earlier.
• R&D costs climbed 60.8% to RMB 108.23 million, driven by higher clinical trial spending and higher raw materials and consumables.
• Administrative expenses more than doubled to RMB 24.62 million, due to higher professional fees tied to listing preparation.
• Cash and cash equivalents rose to RMB 903.76 million as of June 30, 2026, following net proceeds from the global offering.
• LP-003 seasonal allergic rhinitis BLA was accepted by China’s NMPA on Aug. 20, 2026; FDA cleared LP-003 trials for peanut allergy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Longbio Pharma (Suzhou) Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260821-12294135), on August 21, 2026, and is solely responsible for the information contained therein.